Spero Therapeutics (SPRO) Receiving Somewhat Favorable News Coverage, Study Finds
News coverage about Spero Therapeutics (NASDAQ:SPRO) has trended somewhat positive recently, according to Accern. Accern rates the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Spero Therapeutics earned a news impact score of 0.15 on Accern’s scale. Accern also gave news coverage about the company an impact score of 44.2631779374359 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
A number of equities research analysts have recently weighed in on SPRO shares. Zacks Investment Research upgraded shares of Spero Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a research report on Tuesday, January 30th. Oppenheimer set a $30.00 price target on shares of Spero Therapeutics and gave the company a “buy” rating in a research report on Thursday, January 11th. Stifel Nicolaus started coverage on shares of Spero Therapeutics in a research report on Monday, November 27th. They issued a “buy” rating and a $26.00 price target for the company. Bank of America started coverage on shares of Spero Therapeutics in a research report on Monday, November 27th. They issued a “neutral” rating for the company. Finally, Cowen started coverage on shares of Spero Therapeutics in a research report on Monday, November 27th. They issued an “outperform” rating for the company. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company. Spero Therapeutics has an average rating of “Hold” and a consensus target price of $24.25.
Shares of Spero Therapeutics stock traded up $0.03 on Thursday, reaching $14.32. 14,430 shares of the company’s stock traded hands, compared to its average volume of 30,190. Spero Therapeutics has a 1-year low of $9.66 and a 1-year high of $15.40.
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. It is developing SPR994, an oral carbapenem-class antibiotic for use in adults to treat MDR gram-negative infections; SPR741 that has completed Phase I clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic that is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections.
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.